Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. All rights reserved. Unfortunately for longs, OCGN is much closer to the worst of conditions. How can we possibly evaluate a stock on a fundamental basis with that being reality? Maybe OCGN stock will be one of them again. The content is intended to be used for informational purposes only. Keith Speights for It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. That product drives the current bull case for Ocugen stock. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. But if they do, Ocugen stock at the least looks like an intriguing bet. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. All rights reserved. Investors were hopeful that the small drugmaker would be able to win U.S. The Motley Fool has a disclosure policy. What Is the Best EV Stock to Buy Now? It has no treatments to offer the market. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. There's still a chance that the vaccine could receive a green light in Canada. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Ocugen Inc. is a clinical stage biopharmaceutical company. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. So far, that merger hasnt worked out for Histogenics former shareholders. That's right -- they think these 10 stocks are even better buys. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Guys, theres no revenue here! The Ocugen deal is a way to salvage some limited value. If Ocugen goes up, you can still profit. 1125 N. Charles St, Baltimore, MD 21201. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. So, what goes wrong? Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. But any success they find will be without me as a shareholder. Sign up below to get this incredible offer! In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. Nasdaq Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. That doesnt mean success is guaranteed. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. In that list, you can even include penny-stock trader. Can you feel the ground moving beneath your feet? The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. These symbols will be available throughout the site during your session. Nasdaq Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). The Motley Fool recommends Moderna Inc. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. It means that institutional investors focused on the sector largely have passed on the pipeline. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. From a near-term standpoint, there are two key risks. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. That said, for investors who understand the potential downside, there is an intriguing story here. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. As of this writing, Vince Martin has no positions in any securities mentioned. Without NeoCart, that burn likely comes down. The median estimate. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. For priority reviews, the timeline for an approval decision is reduced to six months. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. Learn More. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Please check your download folder. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. You never know when they will suddenly go on a squeeze. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Most biotech companies have intriguing stories on paper; Ocugen is no different. Keith Speights has no position in any of the stocks mentioned. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. market." Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. ET on Friday. Not an offer or recommendation by Stocktwits. Theres even room for more lines. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Hold) without suggesting a price target. The FDA's decision not to issue EUA really wasn't all that surprising, though. That's right -- they think these 10 stocks are even better buys. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. But just because a company does not have crippling debt doesnt mean its a buy. Theres an opportunity here. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. The chances of anything more are small but the rewards could be huge. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Investors were hopeful that the small drugmaker would be able to win U.S. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Histogenics itself highlights the risks involved in small-cap biotech. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. It means that raising capital will be more difficult going forward. Its certainly possible. (See OCGN stock analysis on TipRanks). What Is the Best EV Stock to Buy Now? Part of the proceeds will be used to support its partnership with Bharat. Copyright The Ocugen deal is a way to salvage some limited value. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. This requires no immediate effort on your part. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Keith Speights has no position in any of the stocks mentioned. But realizing value in practice usually is a difficult endeavor. Instead, this appears destined to join the long list of failed biotech startups. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). The short answer is: everything. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. The equity has experienced a continual decline for years. Our 3 Top Picks. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. 1125 N. Charles St, Baltimore, MD 21201. Sign up below to get this incredible offer! Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Typically, I care little about financials with biotechs. 7 Travel Stocks to Buy Banking On Pent-Up Demand. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. If they have solid financials, but their trials continually fail, they will likely not succeed. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Copyright 2023 InvestorPlace Media, LLC. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Type a symbol or company name. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Investors who have owned stocks in the last year have generally experienced some big gains. See disclosure here. 2023 InvestorPlace Media, LLC. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Keith Speights for Its all about choice. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. The Motley Fool has a disclosure policy. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. The Motley Fool->. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Investors should worry about companies with no revenue even under the best of circumstances. Literally, zero. If they invent a miracle treatment for a condition, the money will find its way to the stock. It's hard to say for sure. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. The biotech stock promptly crashed by more than 30%. Do not expect a recovery in Ocugen stock. To make the world smarter, happier, and richer. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. The Motley Fool has a disclosure policy. But there is no question some big-name stocks performed better than others along the way. Create your Watchlist to save your favorite quotes on Nasdaq.com. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. If OCU300 is approved, theres a reasonably large market. Maybe. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Invest better with The Motley Fool. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. However, sometimes the optimism isn't justified. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Copyright This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. All rights reserved. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. 1125 N. Charles St, Baltimore, MD 21201. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. The statistics support having long-term exposure to this asset class. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Written by Even at around 40 cents per share, I would consider Ocugen stock overvalued. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Its worth emphasizing: Ocugen stock is a play with enormous risk. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. This decision. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. Conditions have only become worse since that time. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Long-term debt of $1.6 million is not a back-breaker either. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Accordingly, the analyst rates OCGN a Neutral (i.e. Type a symbol or company name. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. As of this writing, Matt did not hold a position in any of theaforementioned securities. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. quotes delayed at least 15 minutes, all others at least 20 minutes. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Type a symbol or company name. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Keith Speights owns shares of Pfizer. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Create your Watchlist to save your favorite quotes on Nasdaq.com. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. The company initiated its Phase 3 trial of OCU300 back in July 2018. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Do Not Sell My Personal Information (CA Residents Only). Thats the thing with these low-priced penny stocks. Companies will inevitably be optimistic about their prospects for success (at least publicly). It brings in no revenue. The latest closing stock price for Ocugen as of March 03, 2023 is. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. It has real management. First, the balance sheet is in at least decent shape. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Emergency Use . At the time, Ocugen was left for dead. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. This can prove to be a costly lesson to learn. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Cost basis and return based on previous market day close. The average Ocugen stock price for the last 52 weeks is 2.10. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. That's not going to happen now. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad.
Advantages And Disadvantages Of Reports, Murders In Springfield, Mo 2021, Articles O